Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Setrusumab · BPS-804, UX143

Monoclonal antibody · Antagonist of sclerostin (SOST) · developed by Ultragenyx Pharmaceutical

Phase 2/3 Most advanced trial
RARE Developer
4 Registered trials

What is Setrusumab?

Setrusumab is a fully human monoclonal antibody that neutralizes sclerostin, a protein that inhibits bone formation. It is administered by intravenous infusion and is studied in osteogenesis imperfecta, osteopenia and osteoporosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BPS-804, UX143, MOR-05813
Drug type
Monoclonal antibody
Targets
sclerostin (SOST)
Mechanism
Antagonist of sclerostin (SOST)
Pathways
Wnt signaling
Therapy area
Musculoskeletal
Developer
Ultragenyx Pharmaceutical Inc (RARE)
Also in trials of
MREO
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
FPW3780T3E

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06636071 Phase 3 Osteogenesis Imperfecta Active not recruiting RARE
NCT05125809 Phase 2/3 Osteogenesis Imperfecta Active not recruiting MREO
NCT03216486 Phase 2 Osteogenesis Imperfecta Withdrawn MREO
NCT01406548 Phase 2 Osteopenia Completed MREO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Osteogenesis ImperfectaOsteopeniaOsteoporosis

Other drugs acting on SOST

More from Ultragenyx Pharmaceutical

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RARE page.

Follow RARE, the company behind Setrusumab

See RARE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RARE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.